<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02750189</url>
  </required_header>
  <id_info>
    <org_study_id>KUH1010636</org_study_id>
    <nct_id>NCT02750189</nct_id>
  </id_info>
  <brief_title>The Economic Burden of Chronic Obstructive Pulmonary Disease(COPD) in South Korea</brief_title>
  <acronym>BOC</acronym>
  <official_title>The Economic Burden of Patients With COPD in South Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Konkuk University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Konkuk University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate a direct/indirect medical cost and to provide
      evidence establishing efficient strategies to reduce medical costs of COPD in Korea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multi-center research on economic burdens of COPD for a year. It is composed
      of three phases detailed as follow.

      Phase 1: Direct Cost Estimation in COPD patients (N = 400) Direct cost determined as amount
      of money expended to medical institutes for treatment. Estimated costs, based on the
      information from Health insurance review agency(HIRA) and The National Health and Nutrition
      Examination Survey (NHANES) data, are collected.

      Phase 2: Indirect cost Estimation by Sampling Survey in COPD patient Indirect cost is
      extra-expanses excluding hospital fees, including cost for transportation, medical
      instruments, home care services and loss of labor capacity reduction. The information was
      collected by structured questionnaire for 12 weeks.

      Phase 3: Direct/Indirect cost is validated and analyzed based on the collected information
      from phase 1 and 2 according to severity defined by the GOLD guideline.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total cost of COPD</measure>
    <time_frame>1 year</time_frame>
    <description>Korean won, KRW</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of acute exacerbations</measure>
    <time_frame>1 year</time_frame>
    <description>Number of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cost of alternative medication use</measure>
    <time_frame>three months</time_frame>
    <description>We will add up the costs of herbal medicine, health supplement, medical equipments and respiratory rehabilitation. According to patients, the items of alternative medication use would be different.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of productivity lost</measure>
    <time_frame>Last 7days from filling out questionnaires</time_frame>
    <description>Reduction of working hour and monthly income for being late or abscence from work.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol five dimension(EQ-5D)</measure>
    <time_frame>3 months</time_frame>
    <description>Measured by questionnaire based by EQ -5D ( EQ-5D essentially consists of 2 pages - the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS) . The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total number of visits</measure>
    <time_frame>1 year</time_frame>
    <description>primary clinics, emergency department and hospital admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nursing cost</measure>
    <time_frame>1 year (past 1 year before filling questionnaires)</time_frame>
    <description>payment for nurse (Korean won, KRW)</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">390</enrollment>
  <condition>COPD</condition>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Mild Group</arm_group_label>
    <description>FEV₁/FVC ＜70% and FEV₁≥80% direct/indirect cost</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Group</arm_group_label>
    <description>FEV₁/FVC ＜70% and 50%≤FEV₁≤80% direct/indirect cost</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Group</arm_group_label>
    <description>FEV₁/FVC ＜70% and 30%≤FEV₁≤50% direct/indirect cost</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Very Severe Group</arm_group_label>
    <description>FEV₁/FVC ＜70% and FEV₁＜30% direct/indirect cost</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Direct cost</intervention_name>
    <description>Money spent to treat COPD in medical institute based on HIRA</description>
    <arm_group_label>Mild Group</arm_group_label>
    <arm_group_label>Moderate Group</arm_group_label>
    <arm_group_label>Severe Group</arm_group_label>
    <arm_group_label>Very Severe Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Indirect cost</intervention_name>
    <description>extra-expanses excluding hospital fees</description>
    <arm_group_label>Mild Group</arm_group_label>
    <arm_group_label>Moderate Group</arm_group_label>
    <arm_group_label>Severe Group</arm_group_label>
    <arm_group_label>Very Severe Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic Obstructive Pulmonary Disease (COPD)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over 20 years old

          -  COPD patients

        Exclusion Criteria:

          -  Patients who disagree with participating in research
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kwang-Ha NA Yoo, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Konkuk University Hospial</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Konkuk University Hospital</name>
      <address>
        <city>Gwangjin gu</city>
        <state>Seoul</state>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.hira.or.kr/main.do</url>
    <description>Health insurance review agency in south korea</description>
  </link>
  <reference>
    <citation>Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013 Jun 17;5:235-45. doi: 10.2147/CEOR.S34321. Print 2013.</citation>
    <PMID>23818799</PMID>
  </reference>
  <reference>
    <citation>Dang-Tan T, Ismaila A, Zhang S, Zarotsky V, Bernauer M. Clinical, humanistic, and economic burden of chronic obstructive pulmonary disease (COPD) in Canada: a systematic review. BMC Res Notes. 2015 Sep 21;8:464. doi: 10.1186/s13104-015-1427-y. Review.</citation>
    <PMID>26391471</PMID>
  </reference>
  <reference>
    <citation>Løkke A, Hilberg O, Tønnesen P, Ibsen R, Kjellberg J, Jennum P. Direct and indirect economic and health consequences of COPD in Denmark: a national register-based study: 1998-2010. BMJ Open. 2014 Jan 6;4(1):e004069. doi: 10.1136/bmjopen-2013-004069.</citation>
    <PMID>24394800</PMID>
  </reference>
  <reference>
    <citation>Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest. 2000 Feb;117(2 Suppl):5S-9S.</citation>
    <PMID>10673466</PMID>
  </reference>
  <reference>
    <citation>Mannino DM, Higuchi K, Yu TC, Zhou H, Li Y, Tian H, Suh K. Economic Burden of COPD in the Presence of Comorbidities. Chest. 2015 Jul;148(1):138-150. doi: 10.1378/chest.14-2434.</citation>
    <PMID>25675282</PMID>
  </reference>
  <reference>
    <citation>Teo WS, Tan WS, Chong WF, Abisheganaden J, Lew YJ, Lim TK, Heng BH. Economic burden of chronic obstructive pulmonary disease. Respirology. 2012 Jan;17(1):120-6. doi: 10.1111/j.1440-1843.2011.02073.x.</citation>
    <PMID>21954985</PMID>
  </reference>
  <reference>
    <citation>Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006 Sep;28(3):523-32. Epub 2006 Apr 12. Review.</citation>
    <PMID>16611654</PMID>
  </reference>
  <reference>
    <citation>Kim J, Lee TJ, Kim S, Lee E. The economic burden of chronic obstructive pulmonary disease from 2004 to 2013. J Med Econ. 2016;19(2):103-10. doi: 10.3111/13696998.2015.1100114. Epub 2015 Oct 19.</citation>
    <PMID>26414920</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2016</study_first_submitted>
  <study_first_submitted_qc>April 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2016</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Konkuk University Medical Center</investigator_affiliation>
    <investigator_full_name>Kwang-Ha Yoo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

